TOP4!Professor Xu Lin, Jiangsu Cancer Hospital, was selected as the "2021 Chinese Cheung Surgery Expert 50" list

Recently, the official of the Chinese Academy of Sciences "Internet Weekly" officially released the list of "2021 Chinese Cheung Surgery Experts". Professor Xu Lin, a thoracic surgery of Jiangsu Cancer Hospital (Affiliated to Nanjing Medical University), successfully selected the list, ranking fourth; two of the top three experts were academicians.

Professor Xu Lin is the second -level chief physician of Nanjing Medical University, a second -level professor and doctoral supervisor of Nanjing Medical University, an academician (FACS) of the American Academy of Sciences (FACS), and the director of the key laboratory of malignant tumor molecular biology and transformation medicine in Jiangsu Province. The current vice chairman of the Deep Surgery Branch of the Chinese Medical Association, the deputy leader of the Lung Cancer Team of the Chinese Medical Association, the deputy chairman of the Chinese Research Hospital Chemical Surgery Special Committee, the president of the Department of Deep Surgery Branch of the Jiangsu Physician Association, the director of the World Chinese Thoracic Science Society long. Won the first "National Famous Doctor -Excellence Award" and enjoy the special allowance of the State Council.

Professor Xu Lin has been committed to surgical treatment of chest tumors such as center -type lung cancer, trachea, and complex hypertrophy tumors for many years. The first ten kinds of complex chest tumor surgery treatment has been the first, and the treatment effect has reached the international advanced level. Professor Xu Lin's "surgical therapy for local advanced lung cancer" and "surgical therapy for huge longitudinal tumors" were selected into "Classic Surgery of Chinese Contemporary Medical Masters". In 2021, he was successfully published in "Difficulty chest tumor surgery", which was well received in the field of thoracic surgery.

Professor Xu Lin is actively committed to the treatment of minimally invasive lung cancer. Through independent innovation, a series of key technologies such as lung cancer minimally invasive technologies such as lung cancer with "no blood and lung resection", "comprehensive tracheal adhesion method (Xu's needle method)" Severe a number of technical problems in a number of lung cancer minimally invasive surgery.

More than ten years ago, Professor Xu Lin paid close attention to the hot issue of thoracic surgeon on thoracic surgeon. Joint Internal Medicine, Radio and therapy Department, Image Department, and Pathology Section earlier in China to carry out a multi -disciplinary expert clinic (MDT) in China, and now it has served thousands of patients with "pulmonary nodules". The team carried out technical research on the diagnosis, minimally invasive treatment, and comprehensive treatment of the "lung nodule", which significantly improved the level of diagnosis and treatment of the "lung nodule". In 2021, under the approval of the Jiangsu Provincial Commission for Health and Health, the "Jiangsu Provincial Pulmonary Nodule Clinic Platform" was established to benefit the majority of patients with "lung nodes".

With the strong support and help of the hospital leadership team, the thoracic surgery team made great progress in scientific research. In the past five years, he has published more than 200 high -quality papers, won dozens of national and provincial scientific research projects, won the second prize of national scientific and technological progress, the second prize of national natural sciences, the first prize of Jiangsu Province Science and Technology, and other provincial and ministerial science and technology More than ten prizes. It has a high reputation in domestic thoracic surgery. In the "Chinese Hospital's Science and Technology Value Ranking", it has ranked among the top ten of thoracic surgery. He has been rated as the top five East China in East China on the Fudan University Hospital Hospital. At the same time, the thoracic surgery team introduced the "Fourth Generation Da Vinci Robot" since the end of 2019, and completed a total of nearly a thousand early lung cancer robotics surgery. The annual surgical volume exceeded 500 cases, including a series of difficult surgery.

Correspondent Dong Gaochao Zhouwei Nanjing Morning Post/ Love Nanjing reporter Qian Ming

- END -